Learn more about our new preclinical data published in Nature, demonstrating long-term survival with genetically engineered porcine kidneys.


Peter Hanson, D.V.M., Ph.D.

Chief Operating Officer
  • LinkedIn

Dr. Hanson joins eGenesis with more than 20 years of management experience as a biopharmaceutical executive. He was most recently Chief Development Operations Officer at Centrexion Therapeutics, where he oversaw clinical operations and manufacturing development activities. During his tenure, Centrexion obtained Fast Track Designation from the FDA and completed Phase 3 trials in the U.S. and EU for its lead candidate. Previously, Dr. Hanson was Head of R&D and Medical Affairs in animal health at Abbott Laboratories, where he worked closely with contract research organizations and third-party manufacturers to further global business growth and innovation. Prior to Abbott, he held several positions of increasing responsibility at Merial that culminated in becoming global head of project and portfolio management. In this role, he led vaccine and pharmaceutical development projects for companion and production animals.

Dr. Hanson holds a B.A. in biology and earned his D.V.M. from the College of Veterinary Medicine, University of Minnesota. After obtaining his doctorate, he was an associate veterinarian at the Equine and Small Animal Medical Center in Lakeville, Minnesota, before completing a large animal surgery residency and earning an M.S. and Ph.D. in veterinary science from the University of Wisconsin-Madison, where he studied allograft bone transplantation. The 2006 winner of the Animal Pharm Industry Excellence Award for Best New Veterinary Product, Dr. Hanson has received various industry and management accolades. He is also an author on 29 manuscripts and seven patent filings. He has been a member of the American College of Veterinary Surgeons since 1996 and the American Veterinary Medical Association since 1989.

Peter Hanson